Background: Interictal 18F-fluorodeoxyglucose-positron emission topography (FDG-PET) hypometabolism is routinely used in the presurgical workup of children with medically intractable epilepsy (MIE). FDG-PET hypermetabolism, however, is rarely seen, and the significance of this finding in the epilepsy workup is not well established.
Methods: We performed a retrospective study of patients who underwent FDG-PET during the presurgical workup of MIE over a 4-year period, between 1 January 2010 and 31 December 2013, at the Children's Hospital Colorado, CO, USA.
Results: Focal FDG-PET hypermetabolism was identified in 7 (2.2%) of 317 patients. The median age was 124 months, all cases with catastrophic epilepsy. Surface electroencephalography (EEG) performed concomitantly with FDG injections revealed ictal EEG discharges in 2 patients, frequent interictal epileptiform discharges (IEDs) in 3, occasional IEDs in 1, and no IEDs in 1. All 7 patients underwent functional hemispherectomies. Histopathology revealed type 1 focal cortical dysplasia in all patients. Six (86%) were completely seizure-free (Engel class I) and 1 had extremely infrequent seizures (Engel class II) (mean follow-up, 47.4 months).
Conclusion: While a rare finding, interictal PET hypermetabolism does occur, may help identify epileptogenic zones, and assessment to reveal it should be made by concomitant use of surface EEG during PET scans.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000487088 | DOI Listing |
Cancers (Basel)
January 2025
Department of Pathology, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.
: This study evaluates the diagnostic accuracy of [18F]fluorodeoxyglucose ([F]FDG) positron emission tomography (PET) using bone marrow biopsy (BMB) and clinical follow-up as reference standards. It further identifies predictive factors for bone marrow involvement (BMI) in non-Hodgkin lymphoma (NHL) patients. : NHL patients who underwent [F]FDG PET and BMB at diagnosis in a tertiary cancer center were included in this study.
View Article and Find Full Text PDFClin Nucl Med
January 2025
From the Department of Nuclear Medicine, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Subcutaneous nodules and masses as the primary manifestation of diffuse large B-cell lymphoma are exceedingly rare. We present 18F-FDG PET/CT findings of multiple hypermetabolic nodules and masses distributed throughout the body, creating a characteristic "leopard man" appearance on the MIP image, in a 65-year-old man. An excisional biopsy of the right thigh mass confirmed the diagnosis of diffuse large B-cell lymphoma.
View Article and Find Full Text PDFClin Nucl Med
January 2025
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
A 54-year-old man presented with a 1-month history of pain and numbness in the right lower limb. Lumbar spine MRI revealed bone metastases. 18F-FDG PET/CT showed a soft tissue mass with increased 18F-FDG uptake in the rectum, accompanied by multiple hypermetabolic lesions in the bilateral ribs, spine, pelvis, and upper right femur.
View Article and Find Full Text PDFNucl Med Commun
January 2025
Department of Nuclear Medicine, The Second Affiliated Hospital of Shandong First Medical University, Taian.
Objectives: Parkinson's disease (PD) is a neurodegenerative disorder with distinct metabolic alterations in the brain, which are detectable via 18F-FDG PET. This study aims to delineate glucose metabolism patterns and network topology changes across early- and mid-stage PD patients.
Methods: A total of 80 PD patients (Hoehn-Yahr stages 1-3) were retrospectively analyzed, including 40 early-stage and 40 mid-stage cases, along with 40 age-matched healthy controls.
Eur J Surg Oncol
January 2025
Division of Surgical Oncology, Department of Surgery, Northwell Health, New Hyde Park, NY, USA; Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:
Background: F-FDG PET-CT-based host metabolic (PETMet) profiling of non-tumor tissue is a novel approach to incorporate the patient-specific response to cancer into clinical algorithms.
Materials And Methods: A prospectively maintained institutional database of gastroesophageal cancer patients was queried for pretreatment PET-CTs, demographics, and clinicopathologic variables. F-FDG PET avidity was measured in 9 non-tumor tissue types (liver, spleen, 4 muscles, 3 fat locations).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!